Skip to main content
. 2015 Jun 25;6(29):27478–27489. doi: 10.18632/oncotarget.4393

Figure 7.

Figure 7

Blockade of A2B receptors with the selective antagonist PSB1115 reduces VEGF release from tumor stromal cells, including endothelial cells. PSB1115 limits the number of tumor MDSCs, which promote immune suppression and contribute to tumor angiogenesis.